anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A cyclosporine is produced by cultivating an organism for producing an intermediate cyclosporine to recover the intermediate cyclosporine and oxidizing it selectively for producing a cyclosporine. Production of a cyclosporine of structure (II) involves cultivating an organism for producing an intermediate cyclosporine of structure (II) to recover the intermediate cyclosporine and oxidizing it selectively for producing a cyclosporine. A : MeBmt or a residue 3&#39;-desoxi-3&#39;-oxo-MeBmt.Improvements made in the subject of Spanish patent ES2059558 for: &#34;An improved process to produce a cyclosporine&#34;. Improvements made in the subject of Spanish patent ES2059558 consist of a process to produce a cyclosporine of formula II. The invention includes cultivating an organism to produce an intermediate cyclosporine of formula II where A is MeBmt, recovering the intermediate cyclosporine and selectively oxidizing it to produce a cyclosporine of formula II where A is a residual 3&#39;-desoxi-3&#39;-oxo-MeBmt. The compounds thus obtained are useful when the time comes to increase the sensitivity to the therapy with chemotherapeutic drugs or when the time comes to increase the efficacy of said therapy.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an artificial nail composition having improved curability, and further the composition which causes less yellowing and has excellent internal curability.  &lt;P&gt;SOLUTION: The artificial nail composition comprises a component (a) which is a compound having at least one radically polymerizable unsaturated double bond in a molecule and a component (b) which is a photopolymerization initiator selected from the group consisting of (i) acylphosphine oxide type and (ii) the mixtures thereof with α-hydroxyalkylphenone type. The content of the component (b) is 0.05 to 4.00 pts.wt. based on 100 pts.wt. of the component (a). It is preferable that the acylphosphine oxide type photopolymerization initiator is monoacylphosphine oxide and/or bis-acylphosphine oxide and that the α-hydroxyalkylphenone type is 1-hydroxy-cyclohexyl-phenyl-ketone or 2-hydroxy-2-methyl-1-phenyl-propan-1-one.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an additional research tool for elucidating the molecular mechanism of bone modulation, for screening and development of a candidate new drug, and for treatment of bone developmental and bone loss disorders.  &lt;P&gt;SOLUTION: A reagent, a compound, a composition, and a method related to new interactions of the extracellular domain of LRP5, HBM (a variant of the LRP5), and/or LRP6 with Dkk, including Dkk-1 are provided. A specific nucleic acid, a polypeptide, an antibody, an assay method, a diagnostic method, and a treating method are related to and impact on Dkk, LRP5, LRP6, HBM, and Wnt signaling. The Dkk, LRP5, LRP6, HBM, and Wnt are implicated in bone and lipid cellular signaling. Thus, the reagent and the method for modulating lipid levels and/or bone mass are useful in treating and diagnosing abnormal lipid levels and bone mass disorders such as osteoporosis.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a resin structure capable of effectively generating negative ions having beneficial effects on the human body.  &lt;P&gt;SOLUTION: This resin structure contains a substance which generates the negative ions and is deformable by external force. The substance is preferably selected from tourmaline, diatomaceous earth, and a radioactive substance. The resin structure is formed into a thin rib-like shape and composed of a resin having elasticity, such as a silicone rubber, so as to be deformable. A writing material is formed by using the resin structure as its part. The resin structure is, for example, used as a cover for a grip and a knocked part of the writing material to which the external force is given.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient&#39;s sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a data processing unit capable of reliable management of data relating to clinical research.  &lt;P&gt;SOLUTION: The clinical research data processing unit in advance memorizes clinical research registration data wherein the test subject identity and personal details characterizing the subject are coordinated with each other. The clinical research result data that the unit manages include subject identities, clinical research results, and personal details of those subjected to clinical research. The unit determines if there is agreement between personal details in the result data and those in the clinical research registration data and, when there is no agreement other than in gender, it reports that there is data suspected to be erroneous. The unit, in the absence of agreement in gender, abandons the gender in the result data for the gender in the registration data.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oily cleansing agent scarcely exhibiting an irritant feeling without using a polyoxyethylene addition type surfactant in a cleansing process.  &lt;P&gt;SOLUTION: The foam cleansing preparation is obtained by filling a container provided with a pump foamer therewith and forms foam with the pump foamer. The foam cleansing preparation comprising (1) 3-10 pts. wt. of a nonionic surfactant without having a polyoxyethylene group, (2) 70-95 pts. wt. of water, (3) 0.1-1 wt.% of phenoxyethanol and (4) without substantially containing a surfactant having the polyoxyethylene group and an ionic surfactant is provided. A polyglycerol fatty acid ester can especially preferably be exemplified as the nonionic surfactant without having the polyoxyethylene group.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a paste sheet for cutaneous administration, improved in feeling of use and usability by inhibiting pyroligneous acid composition from remaining on the skin and from transferring to a separation film, and keeping the primary effect of the pyroligneous acid for long time, and a manufacturing method for it.  &lt;P&gt;SOLUTION: In this paste sheet for cutaneous administration, a pressure sensitive adhesive layer composed of pyroligneous acid and hydrous gel is formed on a base material and the pressure sensitive adhesive layer is covered with the separation film. Preferably the base material is a laminated base material of a non-woven fabric/air impermeable film or a non-woven fabric/air impermeable film/non-woven fabric. The above sheet is formed by superposing the base material and the separation film between two rollers disposed at a designated space. A first liquid containing pyroligneous acid and a second liquid containing a polyacrylate and a crosslinking agent are mixed, and then dropped in the superposition place to form a gel-like liquid pool. With rotation of two rollers, a gel-like pressure sensitive adhesive layer of a designated thickness is held between the base material and the separation film to manufacture the above paste sheet.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
The invention discloses a preparation method of a traditional Tibetan medicine for treating cerebral thrombosis. The cerebral thrombosis comprises an active component or an active component and medically acceptable auxiliary materials, wherein the active component is prepared by pearl, gastrodia elata, corydalis impatiens, phyllanthus emblica, bear bile powder and agilawood in a certain weight proportion. The traditional Tibetan medicine can be prepared into powders. The traditional Tibetan medicine has the functions of promoting circulation and removing stasis and resisting thromb and flowing venation. Traditional Tibetan medicine is applied to treating cerebrovascular disease due to &#39;dragon&#39;. Traditional Chinese medicine is applied to treating cerebral thrombosis, myocardial infarction, thrombophlebitis, and thromboangitis obliterans.
Protein A chromatography is generally less effective in removing antibody aggregates under typical conditions. Provided is a combination and a method that can significantly improve Protein A&#39;s aggregate removal capability. The combination comprises polyethylene glycol (PEG) and a salt (chaotropic or kosmotropic) as wash and elution buffer additives. The synergistic effect of salt and PEG results in almost complete separation of monomer from aggregates. For the case used for demonstration, in comparison with the control run the optimized procedure reduces aggregates in elution pool from 20% to 3-4%. This new method, by facilitating aggregate removal at the capture step, improves the overall robustness of downstream process.
The invention relates to a medicine for treating the Parkinson&#39;s disease. The medicine is prepared from, by weight, 12 parts of Habenaria ciliolaris Kranz1., 12 parts of japonica china fern rhizome, 20 parts of concha margaritifera, 8 parts of radix clematidis, 12 parts of poria with hostwood, 23 parts of mazus stachydifolius and 18 parts of ramulus uncariae cum uncis. Habenaria ciliolaris Kranz1. strengthens waist and tonifies kidney, clears heat and promotes urination, and eliminates toxin; japonica china fern rhizome clears away heat and toxic materials, kills insects to stop bleeding, and expels wind-damp; concha margaritifera calms liver and suppresses yang, soothes nerves and arrests convulsion, clears liver and improves vision; radix clematidis dispels wind and eliminates dampness, and activates meridians to stop pain; poria with hostwood calms and soothes nerves, and promotes urination; mazus stachydifolius clears away heat and toxic materials, and cools blood and eliminates stasis; ramulus uncariae cum uncis clears away heat and calms liver, and relieves spasm by subduing liver-wind. The medicine materials are used together for achieving the functions of soothing liver to subside endogenous wind, tonifying qi and kidney, eliminating phlegm by cooling, and activating meridians to stop fibrillation. It is proved through clinical experiments that the Parkinson&#39;s disease can be safely and effectively treated.
The application provides methods for determining a patient&#39;s risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient&#39;s risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and/or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131/H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.
The present invention discloses injected bone morphogenetic protein using fibrin as carriers, which is suitable for clinically treating fractures, nonunion and bone defect. Fibrin separated from patients&#39; blood or healthy blood donors&#39; blood is used as carriers, compounded cow bone morphogenetic protein is directly injected to the local injury part percutaneously to perform the functions of slow release of the carriers, and new bone growth promotion, fracture union and wound repair acceleration of the bone morphogenetic protein. The present invention does not result in immunogenicity or rejection reaction, and has no adverse reaction after implanted in the body. Before used, the fibrin is liquid, can be rapidly solidified in the body, and can be shaped randomly. In addition, the functions of hemostasis and cementation of the fibrin are favourable for preventing and curing local hematoma, which provides a favorable local environment for the regeneration and the union of bones. Animal experiments and clinical tests prove that the present invention has exact treatment effect, wide range of application, easy operation, safety and reliability.
FIELD: medicine, stomatology. SUBSTANCE: composition has sedimentary silicon dioxide that is low-structural silicon dioxide with narrow distribution of soft particles by their size, their mean size is in the range from 8 to 14 micron, value of oil absorption is in the range from 60 to 120 cm 3 /100 and empty space volume as measured by mercury intrusion is from 1.0 to 4 cm 3 /g. Silicon dioxide has index &#34;cleansing ratio relative to film&#34; from 70 to 140 and abrasion value of radioactive dentine from 60 to 130 where ratio of indicated values is at least 1:1. When particle size of silicon dioxide (in microns) is increased then value of abrasion of radioactive dentine remains to be constant. EFFECT: improved teeth cleansing, enhanced effectiveness of composition. 10 cl, 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a molding having increased recognizability of a letter and/or a figure and to provide a method for producing the same in a realistically usable form.  &lt;P&gt;SOLUTION: This molding comprising a central molding part and an outside molding part having a color different from that of the central molding part in which the letter and/or the figure shown by the central molding part and/or the outside molding part is recognized by difference in color of the central molding part recognized through the outside molding part is contrived. The molding comprises an upper punch composed of double structure of a central punch and an outer punch surrounding the outer periphery of the central punch. The molding has a projecting part forming the letter and/or the figure on the surface of the tip part of at least one of the upper and a lower punches or the shape of the tip part of the central punch which forms the letter and/or the figure. Both the central and the outer punches are produced by using a compression molding means to be slid and compressed.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PURPOSE:To obtain a pharmaceutical composition useful as a remedy for circulatory diseases, respiratory diseases, central nervous diseases, etc., by using a fraction obtained by extracting lotus seed embryo with water and/or methanol or ethanol as an active component. CONSTITUTION:Lotus sprout (embryo of lotus seed) is extracted with water at about 60 deg.C for 1-12hr and the extraction residue is extracted with methanol or ethanol at &lt;=60 deg.C to obtain each extraction fraction. The extraction fractions are solidified by removing water, methanol or ethanol by freeze-drying, vacuum distillation, etc. These solidified fractions are usually used separately, however, both fractions may be used in combination. The agent is useful as a remedy for circulatory diseases (e.g. hypertension, thrombosis or embolism), respiratory diseases (e.g. bronchial asthma or bronchitis), central nervous diseases (e.g. insomnia), etc.
The present invention provides a system, and method for medical analysis treatment. The system includes a computer system (100) for storing a plurality of databases. The databases maintain medical research data regarding analyte characteristics, and vitamin/nutrient characteristics. A first database maintains a plurality of analyte records, wherein each record holds information regarding a particular analyte that was determined from the results of testing a human test group. Each analyte record includes a low value, a high value, and a target value. A second database maintains a plurality of vitamin/nutrient records wherein each vitamin/nutrient record includes analytes associated with the particular vitamin/nutrient, and an analyte level indicative of vitamin/nutrient that may have supportive effect. The method matches an individual&#39;s bodily fluid laboratory results with the databases to identify supportive nutrient metabolic agents for each of the analytes within the lab report, potential negative drug reaction to each analyte as they pertain to the individual&#39;s analyte status.
The following relates to medical device technology. In one aspect, a score is calculated based on a patient&#39;s vital sign information. The score is displayed in a center circle. Spokes corresponding to individual vital signs may extend from the center circle. The spokes may be color coded based on a subscore (e.g. severity level) of the vital sign that they correspond to. A thickness of each spoke may be based on subscore of the corresponding vital sign.
PURPOSE:To produce a make-up cosmetic for masking the pores, chapped skin, wrinkles, etc., by compounding granular silicone having slipperiness, spreadability and adhesivity and containing a silicone oil as an oil having high affinity to the skin. CONSTITUTION:This make-up cosmetic is produced by compounding a specific amount of a granular silicone containing a silicone oil. The amount of the granular silicone is preferably 0.5-30 pts.wt., especially 3-15 pts.wt. The ratio of (titanium oxide+zinc oxide)/(granular silicone) in the cosmetic is preferably &lt;2.5. The make-up cosmetic is preferably further incorporated with 0.5-20 pts.wt. of a polyhydric alcohol (e.g. propylene glycol, dipropylene glycol, 1,3- butylene glycol or glycerol) and the ratio of the polyhydric alcohol to the total amount of the oil is preferably &gt;0.2.
NEW MATERIAL:The compound of formula I (R is H or methyl; R&lt;1&gt; is pyridyl, furyl or thienyl; R&lt;2&gt; is lower alkyl, F-substituted lower alkyl or cyclopropyl). EXAMPLE:N-cyclopropyl-3-(2-thienyl)acrylamide. USE:A central muscle relaxant. It has excellent muscle relaxation action and rigidity remission action and is useful as a therapeutic agent for myospasmus dolorosa accompanying to the locomotive disease such as lumbago, dorsalgia and herniated disk and as a therapeutic agent for spasmodic paralysis such as cerebrovascular disorder. PREPARATION:The compound of formula I can be produced by reacting an alkenoic acid of formula II with a halogenation agent (e.g. thionyl chloride) and reacting the resultant acid halide of formula III (X is halogen) with an amine of formula R&lt;2&gt;-NH2.
A composition for treating opioid withdrawal and method of manufacture and administration of the composition creates a synergistic combination of cannabinoids, terpenoids, herbs, and medicinal mushrooms that help to eliminate the symptoms of opioid withdrawal by creating a medicinal entourage. The composition combines: between about 2.5 to 100 milligrams of a cannabinoid, between about 0.084 to 33.6 milligrams of a terpenoid, between about 0.5 to 3000 milligrams of an herb, and between about 25 to 2500 milligrams of a medicinal mushroom. The composition is orally administered in a lipid-enclosed capsule form. The terpenoid has a lipophilic nature that enhances the bioavailability of the cannabinoid. The herb works with the body&#39;s endocannabinoid system to enhance pain relief capacity of the cannabinoid, so as to help inhibit symptoms of opioid withdrawal. The medicinal mushroom comprises a psychedelic drug that creates a therapeutic effect with the cannabinoid to inhibit symptoms of opioid withdrawal.
PURPOSE:To obtain the subject peptide, having a specific amino acid sequence, capable of inducing a viral neutralizing antibody on Aujeszky&#39;s disease virus gIII and useful for designing, etc., a peptide vaccine effective in phylaxis of the Aujeszky&#39;s disease virus. CONSTITUTION:A virus is purified from Aujeszly&#39;s disease virus Indiana S strain according to a conventional method, treated with proteinase K and then with phenol-chloroform to provide a virus DNA. Two primers are bound to both terminals of the resultant gIII gene according to a base sequence of the gIII gene in Aujeszky&#39;s disease virus Becker strain and amplified by a polymerase chain reactional(PCR) method. The prepared sample after the amplification is subjected to agarose electrophoresis to cut out a band having a length of the gIII gene. The obtained band is subsequently bound to a vector to afford a recombinant plasmid, which is then used to transform Escherichia coli. The prepared transformant is cultured in a culture medium to provide the objective peptide constructed from an amino acid sequence expressed by the formula.
The invention relates to a health management system combined with a smart bed set. Different from a medical system, during the sleep time necessary in people&#39;s daily life, the system is provided to use a smart bed or pillow to unknowingly detect the accumulated data and compare and analyze the accumulated data for a long time without affecting the quality of life, so as to break through the limitations of time and space when people go to the hospital for examination and to assist in early detection of possible diseases thereby achieving the effect of health management. The system includes a physiological information detection module, a database, an analysis unit, and a display module, which are all connected to the smart bed set by signals. The physiological signals of the user during daily sleep can be detected and then analyzed by the analysis unit to be displayed on the display module, or accumulated and continuously stored in the database for comparative analysis, which can be used to find the timing of physiological abnormalities early. The database can be built on a cloud platform, a computer or a smart phone for users to perform personal health management or provide medical staff as a reference for medical purposes, which is extremely industrially usable and progressive. Moreover, the system further includes a smart bed set having a data processing module and a wired or wireless transmission module. The physiological information detection module is connected to the data processing module. The database has physiological data statistics. The analysis unit can read the information of the database and is connected to the wired or wireless transmission module. The display module is connected to the analysis unit by signals. The database and the analysis unit are application programs built in the external networking device and the display module is a display screen of the external networking device.